HiberCell
1 follower
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” they are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumo... Read more
Org chart
Jonathan Lanfear
President & CEO
Jonathan Lanfear
Collapse
Ari Nowacek
Co-Founder & Chief Business Officer
Joseph Talamo
Chief Financial Officer
José Iglesias
Consultant Chief Medical Officer
Nandita Bose
VP of Translational Immunology
David Surguladze
VP of Preclinical Pharmacology
Jehan Rowlands
VP of Regulatory Affairs
Crissy Dudgeon
Associate Director, InVitro Translational Oncology
Beth Johnson
Executive Assistant & Officer Manager
Cindy Jacobs Ph.D., M.D.
Independent Board Director
Eric Lightcap
Executive Director
Glenn Youngblood
Exec. Director Quality
Jeremy Drees
Associate Director, Translational Immunology
Julio Aguirre-Ghiso
Scientific Founder, SAB member
Kyle Michel
Manager, Quality
Michael Danielson
Senior Director Process Development
Paulette Mattson
Senior Manager, Clinical Trials
Sho Fujisawa
Manager of Imaging Core Facility
Trinda Jevne
Clinical Quality Assurance Manager
Teams
View all
